S&P 500

5.304,72

0,70%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
GRI Bio Inc (GRI)
GRI Bio Inc (GRI) Notícias

GRI

GRI Bio (GRI)

GRI Bio Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:GRI

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
22/05/2024	10:15	GlobeNewswire Inc.	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs	NASDAQ:GRI	GRI Bio Inc
21/05/2024	09:35	GlobeNewswire Inc.	GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)	NASDAQ:GRI	GRI Bio Inc
20/05/2024	09:45	GlobeNewswire Inc.	GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)	NASDAQ:GRI	GRI Bio Inc
14/05/2024	10:05	GlobeNewswire Inc.	GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase	NASDAQ:GRI	GRI Bio Inc
13/05/2024	09:00	GlobeNewswire Inc.	GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:GRI	GRI Bio Inc
29/04/2024	09:45	GlobeNewswire Inc.	GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity	NASDAQ:GRI	GRI Bio Inc
25/04/2024	10:15	GlobeNewswire Inc.	GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar	NASDAQ:GRI	GRI Bio Inc
16/04/2024	09:35	GlobeNewswire Inc.	GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent	NASDAQ:GRI	GRI Bio Inc
08/04/2024	09:35	GlobeNewswire Inc.	GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference	NASDAQ:GRI	GRI Bio Inc
01/04/2024	08:35	GlobeNewswire Inc.	GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:GRI	GRI Bio Inc
28/03/2024	10:00	GlobeNewswire Inc.	GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference	NASDAQ:GRI	GRI Bio Inc
14/03/2024	09:45	GlobeNewswire Inc.	GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators	NASDAQ:GRI	GRI Bio Inc
04/03/2024	10:30	GlobeNewswire Inc.	GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	NASDAQ:GRI	GRI Bio Inc
02/02/2024	10:00	GlobeNewswire Inc.	GRI Bio Announces Pricing of $5.5 Million Public Offering	NASDAQ:GRI	GRI Bio Inc
26/01/2024	10:05	GlobeNewswire Inc.	GRI Bio Announces Reverse Stock Split	NASDAQ:GRI	GRI Bio Inc
05/12/2023	11:05	GlobeNewswire Inc.	GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	NASDAQ:GRI	GRI Bio Inc
27/11/2023	10:35	GlobeNewswire Inc.	GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	NASDAQ:GRI	GRI Bio Inc
15/11/2023	10:05	GlobeNewswire Inc.	GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:GRI	GRI Bio Inc
31/10/2023	09:45	GlobeNewswire Inc.	GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases	NASDAQ:GRI	GRI Bio Inc
19/10/2023	09:45	GlobeNewswire Inc.	GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference	NASDAQ:GRI	GRI Bio Inc
17/10/2023	09:35	GlobeNewswire Inc.	GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression	NASDAQ:GRI	GRI Bio Inc
11/10/2023	10:05	GlobeNewswire Inc.	GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference	NASDAQ:GRI	GRI Bio Inc
05/10/2023	09:45	GlobeNewswire Inc.	GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions	NASDAQ:GRI	GRI Bio Inc
06/09/2023	10:05	GlobeNewswire Inc.	GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:GRI	GRI Bio Inc
23/08/2023	10:00	GlobeNewswire Inc.	GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR	NASDAQ:GRI	GRI Bio Inc
14/08/2023	09:05	GlobeNewswire Inc.	GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:GRI	GRI Bio Inc
07/08/2023	09:35	GlobeNewswire Inc.	GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models	NASDAQ:GRI	GRI Bio Inc
03/08/2023	09:30	GlobeNewswire Inc.	GRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference	NASDAQ:GRI	GRI Bio Inc
24/07/2023	10:00	GlobeNewswire Inc.	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event	NASDAQ:GRI	GRI Bio Inc
05/07/2023	09:45	GlobeNewswire Inc.	GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series	NASDAQ:GRI	GRI Bio Inc